Objectives: ITo examine the economic impact of Alzheimer's disease (AD) as the disease progresses on patients' medical costs and caregivers' productivity.

Design: A 12-page, self-administered mail survey, fielded in November 1999.

Setting: Households with AD caregivers, selected from a nationwide (U.S.) consumer database.

Participants: One thousand seven hundred fifteen caregivers of noninstitutionalized AD patients.

Measurements: Disease progression was measured using a scale of symptom frequency and measures of instrumental and physical functioning. Cost components included hospital days, physician visits, and emergency room visits. Lost productivity was assessed using hours per week that caregivers provided care and the number of days that they missed from work because of caregiving.

Results: The direct costs of caring for AD patients for 6 months totaled $3,129, whereas the indirect costs were $26,080. Patients with more-frequent symptoms used all healthcare resources, including the hospital, emergency room, and physicians, more often than those with less-frequent symptoms. Those with lower levels of physical and instrumental functioning also used the hospital and physicians more often than those with higher levels of physical and instrumental functioning. Caregivers of these more severely impaired patients spent more hours providing care and reported missing more work than those caring for higher-functioning patients. These relationships remained after controlling for potentially confounding factors.

Conclusions: This large study of patients at all stages of AD shows that the direct and indirect costs of AD are considerably lower for patients with fewer symptoms. Longitudinal studies will determine the impact on the overall cost of care of interventions that reduce symptoms and maintain patients at earlier stages of the disease.

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1532-5415.2002.50065.xDOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
8
emergency room
8
indirect costs
8
levels physical
8
physical instrumental
8
instrumental functioning
8
patients
7
disease
5
impact symptom
4
symptom severity
4

Similar Publications

The blood-brain-barrier prevents many imaging agents and therapeutics from being delivered to the brain that could fight central nervous system diseases such as Alzheimer's disease and strokes. However, techniques such as the use of stapled peptides or peptide shuttles may allow payloads through, with bioconjugation achieved bio-orthogonal tetrazine/norbornene click chemistry. A series of lanthanide-tetrazine probes have been synthesised herein which could be utilised in bio-orthogonal click chemistry with peptide-based delivery systems to deliver MRI agents through the blood-brain-barrier.

View Article and Find Full Text PDF

Background: Ultra-processed food (UPF) consumption has been linked with higher risk of mortality. This multi-centre study investigated associations between food intake by degree of processing, using the Nova classification, and all-cause and cause-specific mortality.

Methods: This study analyzed data from the European Prospective Investigation into Cancer and Nutrition.

View Article and Find Full Text PDF

Background: The number of individuals living alone with dementia is increasing throughout the world, and they have unique needs that are poorly understood. The aim of this integrative review was to understand the characteristics, needs, and perspectives of individuals living alone with dementia as well as the available community resources to guide future research and clinical practice.

Methods: Electronic (PubMed, CINAHL, and PsycINFO) and manual searches were utilized to identify articles using MeSH terms.

View Article and Find Full Text PDF

Novel multipotent conjugate bearing tacrine and donepezil motifs with dual cholinergic inhibition and neuroprotective properties targeting Alzheimer's disease.

RSC Med Chem

January 2025

Área de Neurofisiología celular, Instituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia Medellín Colombia

In this work, we developed potential multifunctional agents to combat Alzheimer's disease. According to our strategy, fragments of tacrine and donepezil were merged in a unique hybrid structure. After successfully synthesizing the compounds, they were evaluated for their dual AChE/BuChE inhibitor potential and neuroprotector response using a glutamate-induced excitotoxicity model.

View Article and Find Full Text PDF

An approach to predict and inhibit Amyloid Beta dimerization pattern in Alzheimer's disease.

Toxicol Rep

June 2025

Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, West Bengal 700054, India.

Alzheimer's Disease (AD) is one of the leading neurodegenerative diseases that affect the human population. Several hypotheses are in the pipeline to establish the commencement of this disease; however, the amyloid hypothesis is one of the most widely accepted ones. Amyloid plaques are rich in Amyloid Beta (Aβ) proteins, which are found in the brains of Alzheimer's patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!